Plasma neuroleptic and prolactin levels in mentally retarded patients. 1980

M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen

UI MeSH Term Description Entries
D008297 Male Males
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D008653 Mesoridazine A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE. Serentil
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013881 Thioridazine A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA. Aldazine,Apo-Thioridazine,Meleril,Mellaril,Melleretten,Melleril,Melleryl,Melzine,Rideril,Sonapax,Thioridazine HCL,Thioridazine Hydrochloride,Thioridazine-Neurazpharm,Thiozine,Apo Thioridazine,ApoThioridazine,Thioridazine Neurazpharm,ThioridazineNeurazpharm
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
January 1982, Psychopharmacology bulletin,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
September 1993, Seizure,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
May 1996, Biological psychiatry,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
August 1982, The Journal of nervous and mental disease,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
January 1992, Duodecim; laaketieteellinen aikakauskirja,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
January 1988, The Journal of clinical psychiatry,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
August 1983, Psychiatry research,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
November 1986, Journal of adolescent health care : official publication of the Society for Adolescent Medicine,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
March 1969, American journal of mental deficiency,
M Linnolia, and M Viukari, and K Vaisanen, and J Auvinen
January 1991, Schizophrenia bulletin,
Copied contents to your clipboard!